NeuroSearch AS (NEUR) - Financial and Strategic SWOT Analysis Review

December 2018 | 42 pages | ID: N39BD10C489EN
GlobalData

Abstracts

NeuroSearch AS (NEUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Key manufacturing facilities – A list of key manufacturing facilities of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

NeuroSearch AS (NeuroSearch) focuses on the development of novel pharmaceutical agents for the treatment of various disorders of central nervous system (CNS) through license agreements with other life science companies. The company divested all rights of Huntexil for the treatment of patients with Huntington's disease to Teva Pharmaceuticals. It also sold all the preclinical and clinical assets, and further development of NS2330 (tesofensine) and NS2359 as well as of any potential drugs based on NS2330 or NS2359 to Saniona A/S and Saniona AB (Saniona). NeuroSearch is entitled to receive a one-time cash payment from Saniona and milestone payments from Teva. NeuroSearch is headquartered in Hallerup, Denmark.

NeuroSearch AS Key Recent Developments

Aug 30,2018: NeuroSearch – H1 report 2018
Dec 05,2017: Update on NeuroSearch’s business status and future
Aug 31,2017: NeuroSearch – H1 report 2017
Feb 24,2017: NeuroSearch releasing Annual Report 2016

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

NeuroSearch AS - Key Facts
NeuroSearch AS - Key Employees
NeuroSearch AS - Key Employee Biographies
NeuroSearch AS - Major Products and Services
NeuroSearch AS - History
NeuroSearch AS - Company Statement
NeuroSearch AS - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
NeuroSearch AS - Business Description
NeuroSearch AS - SWOT Analysis
SWOT Analysis - Overview
NeuroSearch AS - Strengths
NeuroSearch AS - Weaknesses
NeuroSearch AS - Opportunities
NeuroSearch AS - Threats
NeuroSearch AS - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

NeuroSearch AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
NeuroSearch AS, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
NeuroSearch AS, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 30, 2018: NeuroSearch – H1 report 2018
Dec 05, 2017: Update on NeuroSearch’s business status and future
Aug 31, 2017: NeuroSearch – H1 report 2017
Feb 24, 2017: NeuroSearch releasing Annual Report 2016

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

NeuroSearch AS, Key Facts
NeuroSearch AS, Key Employees
NeuroSearch AS, Key Employee Biographies
NeuroSearch AS, Major Products and Services
NeuroSearch AS, History
NeuroSearch AS, Subsidiaries
NeuroSearch AS, Key Competitors
NeuroSearch AS, Ratios based on current share price
NeuroSearch AS, Annual Ratios
NeuroSearch AS, Annual Ratios (Cont.1)
NeuroSearch AS, Interim Ratios
NeuroSearch AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
NeuroSearch AS, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
NeuroSearch AS, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

NeuroSearch AS, Performance Chart (2013 - 2017)
NeuroSearch AS, Ratio Charts
NeuroSearch AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
NeuroSearch AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

COMPANIES MENTIONED

Orexigen Therapeutics Inc
IXICO Plc
H. Lundbeck AS
Exiqon AS
Arena Pharmaceuticals Inc
Acadia Pharmaceuticals AS